Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

IRVING, Texas--(BUSINESS WIRE)--Apr 25, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of a review article covering the company's Synthetic Triterpenoid programs in the May 2007 issue of the prestigious journal "Nature Reviews Cancer."

The article, "Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer," by researchers and Reata scientific collaborators from the Dartmouth Medical School Karen T. Liby, Mark M. Yore and Michael B. Sporn, focuses on two new classes of multifunctional drugs that it reports can prevent and treat cancer in experimental animals. One of Reata's lead clinical candidates, from one of the classes the article describes, the Synthetic Triterpenoids, is entering advanced clinical trials for deadly, late-stage cancers.

The article describes the Synthetic Triterpenoids as a new class of non-toxic and highly multifunctional drugs that have applications for the prevention and treatment of not only cancer, but also of many other diseases with an inflammatory component.

"An outstanding body of work is emerging on the Synthetic Triterpenoids from many top academic collaborators," commented Warren Huff, Reata's CEO. "Dr. Sporn and his team have provided an excellent summary of the broad research currently underway on these compounds and the underlying biological pathways they modulate. Reata is delighted to have the opportunity to collaborate with these researchers in taking take these important new drugs forward to provide a clinical benefit for patients with cancer and other diseases."

Reata in-licensed the complete series of Synthetic Triterpenoids from Dartmouth and the University of Texas M.D. Anderson Cancer Center in 2004. RTA 402, the lead agent from this series, has recently begun Phase 2 clinical studies for cancer and anti-inflammatory diseases. An ongoing Phase 1 study in cancer patients has demonstrated
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:11/6/2009)..., SARASOTA, Fla., Nov. 6 /PRNewswire-FirstCall/ ...nounced that it has signed a definitive agreement ...roprietary medical devices. The Verathon Board of...osing is subject to customary regulatory approvals...roval. The parties expect the closing to be compl...
(Date:11/6/2009)..., PRINCETON, N.J., Nov. 6 /PRNewswire-FirstCall/...DSCI), a provider of advanced wound care products,... results before market on Monday, November 16, 200...me day to discuss the results at 11:00 am EST. Int...ic) or (857) 350-1684 (international), with passco...
(Date:11/6/2009)..., LEXINGTON, Ky., Nov. 6 /PRNewswire-FirstCall/ ... Board: VHGI) confirmed today that the previously ... related assets to Wound Management Technologies, ...ard of Directors and shareholders of VHGI. ,,...he potential stock dividend, royalty stream and ca...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4CorVel Announces Revenues and Earnings 47873 1CorVel Announces Revenues and Earnings 47873 2CorVel Announces Revenues and Earnings 47873 3CorVel Announces Revenues and Earnings 47873 4CorVel Announces Revenues and Earnings 47873 5CorVel Announces Revenues and Earnings 47873 6Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 47872 1Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 47872 2DC Government Renews Certified Business Enterprise Classification to Language Interpretation and Translation Firm 47870 1DC Government Renews Certified Business Enterprise Classification to Language Interpretation and Translation Firm 47870 2DC Government Renews Certified Business Enterprise Classification to Language Interpretation and Translation Firm 47870 3
...gs of amylin/leptin synergy and translational Phas... Proceedings of the National Academy of S...O, May 5 Amylin Pharmaceuticals, Inc.,(Nasdaq: A... clinical study,evaluating various dosing combinat...one amylin, and recombinant human leptin (r-metHuL...
...d Improvement in Symptoms Both in the Short and Lo...INGTON, Del., May 5 AstraZeneca (NYSE:,AZN) today...iapine,fumarate) Extended-Release Tablets for the ...eneralized anxiety disorder (GAD) in adult patient...ay at the 161st Annual,Meeting of the American Psy...
Other Medicine Technology:Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 2Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 3Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 4Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14
(Date:11/7/2009)..., HOUSTON, Nov. 7 ...sented Lisa James, Director of Health at the Famil...Distinguished Service today at its semi-annual pol...d Service is the highest honor the AMA House of De... http://www.newscom.com/cgi-bin/prnh/20081209/A...
(Date:11/7/2009)..., HOUSTON, Nov. 7 Calling thi...ociation (AMA), the AMA President J. James Rohack,... physicians from all state and medical specialty s...olicy-making meeting, where health system reform w...com.com/cgi-bin/prnh/20081209/AMALOGO ) ,, "O...
(Date:11/7/2009)..., WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ ...nearing, antichoice extremists are holding the ent...nda. They are demanding that the bill go far beyon... been incorporated into the original bill. In an ...d on early Saturday afternoon, antichoice Democrat...
(Date:11/7/2009)..., WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ ...e House of Representatives to vote for the Stupak-..., "The Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-L... federal law on abortion funding and conscience pr...a Act (H.R. 3962)," they said. ,, The letter wa...
(Date:11/7/2009)... WASHINGTON, Nov. 7 Americans United for Life Act...f the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lip...y federal money from going to abortion in health c...President and CEO Dr. Charmaine Yoest said, "Ameri...Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-...
Breaking Medicine News(10 mins):Health News:AMA Honors Family Violence Prevention Expert 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2
...and Men From 46 States and 7 ...,900 participants in this,weekend,s fifth annual A...illion to advance access to care and finding a cur... grants, with millions,more slated to be awarded t...
...OCS, Inc. and,Press Ganey Associates, Inc. today a...eby the companies have combined their best-of-bree...of products for the home,health care industry. The...ient outcomes and financial performance. The first...
...udy finds , SUNDAY, Oct. 7 (HealthDay News) -- Men...fall have a better chance of survival than those d...Norwegian men suggests. , "Summer and autumn month...at this possibility should be studied further," st...
...,transcript of a radio address by President Bush t... important commitment of the Federal government is...health care. Most of these children are,covered by...struggling, we have the State Children,s Health In...
...d to MRI exposure, scientists say , FRIDAY, Oct. 5...a newly identified disease called nephrogenic syst..., U.S. researchers report. , The researchers also ... condition characterized by a thickening and harde...
...vascular disease , , FRIDAY, Oct. 5 (Healt...re having problems achieving or sustaining erectio...tile dysfunction, or impotence, affects more than ...of research ties erectile dysfunction to vascular ...
Other Medicine News:Health News:Fifth Annual Avon Walk for Breast Cancer New York Raises $10.2 Million 2Health News:Fifth Annual Avon Walk for Breast Cancer New York Raises $10.2 Million 3Health News:OCS and Press Ganey Partner to Create Joint Analysis of Outcomes and Satisfaction 2Health News:Prostate Cancer Survival Varies by Season 2Health News:Radio Address by President Bush to the Nation 2Health News:New Kidney Disease Can Be Fatal 2Health News:Erectile Dysfunction: A Harbinger of Heart Trouble 2Health News:Erectile Dysfunction: A Harbinger of Heart Trouble 3
... the functional management of grade I, II, and III...ed aircell, the brace provides focused, pneumatic ...upporting the arm and shoulder. A detachable sling...al arm support and helps to unload the waist strap...
Humeral Stabilizing System (HSS)
Humerus Fracture Brace
Functional Arm Brace
Medicine Products: